AliveDx

Name

AliveDx

Legal name

AliveDx Suisse S.A.

Website

https://alivedx.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

In-Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Surgical and Medical Instrument Manufacturing (339112)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Autoimmune, Allergy & Specialized Immunology Diagnostics (HLAHAAAK)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

Keywords

• In-vitro diagnostics
• Autoimmune disease testing
• Blood bank reagents
• Microarray immunoassays
• Clinical laboratory instruments

Headquarters

HQ city

Eysins

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. MosaiQ Platform and Assays: Sale of the MosaiQ automated multiplex microarray instrument platform along with consumable assay panels (AiPlex CTDplus, AiPlex CD, AiPlex VAS, AiPlex APS, AllergyPlex COMBO). The platform is sold as an instrument with recurring revenue from proprietary microarray consumables and reagents. Revenue model combines hardware instrument sales with recurring consumable reagent revenue.
2. Alba Blood Bank Reagents: Sale of manual blood bank reagent products including ABO/RhD antisera, red blood cells, anti-human globulin, rare antisera for extended phenotyping, and enhancement media. The Alba portfolio includes 81 FDA-cleared and 74 CE-marked products sold directly to blood banks, hospitals, and labs globally.
3. Alba OEM Products: Supply of intermediate products for blood typing or related applications on an Original Equipment Manufacturer (OEM) basis to other manufacturers and industry partners. Partnering leverages over 30 years of development, manufacturing, and marketing expertise in transfusion diagnostics.
4. LumiQ IFA Platform and Consumables: Sale of the LumiQ automated immunofluorescence assay platform and associated reagents. The LumiQ system complements MosaiQ by providing a turnkey solution for autoimmune diagnostics combining screening and identification of autoantibodies.
5. Technical Support and Services: Technical support services including evaluation protocols, product usage guidance, and dedicated expert support for Alba products. Service and support offerings include service engineers, application specialists, remote monitoring, and troubleshooting support.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

Core offering

AliveDx designs, manufactures, and sells in-vitro diagnostic instruments and consumable assay panels for autoimmune disease, allergy, and transfusion medicine testing. Its product ecosystem centers on the automated MosaiQ multiplex microarray platform, the LumiQ all-in-one immunofluorescence solution, and the Alba portfolio of manual blood bank reagents. Revenue is generated from instrument sales paired with recurring consumable microarray and reagent sales, supported by technical services and an OEM supply program.

Product overview

AliveDx is an established commercial-stage in-vitro diagnostics company with over 30 years of experience, offering a unified portfolio of automated and manual diagnostic solutions. The core product ecosystem centers on three main platforms: MosaiQ (fully automated high-throughput multiplex microarray platform), LumiQ (all-in-one immunofluorescence assay solution), and Alba (manual blood bank reagents). The MosaiQ platform serves as the primary automated testing system, with specialized assay modules including AiPlex CTDplus (Connective Tissue Diseases), AiPlex CD (Celiac Disease), AiPlex VAS (Vasculitis), AiPlex APS (Antiphospholipid Syndrome), and AllergyPlex COMBO (Allergy testing). The Alba line provides manual blood bank reagents including antisera, red blood cells, and enhancement media, complemented by OEM solutions and technical support services. This integrated approach enables testing across autoimmune diseases, allergies, and immunohematology applications.

Differentiator

Problem solved

Functional benefit

Brands

• MosaiQ: Fully automated high-throughput platform for multiplex testing of autoimmune diseases and allergies using advanced microarray technology.
• LumiQ
• Alba
• AiPlex

Products and services

• MosaiQ Platform
• LumiQ
• Alba Blood Bank Reagents
• MosaiQ AiPlex CTDplus Assay
• MosaiQ AiPlex CD Assay
• MosaiQ AiPlex VAS Assay
• AllergyPlex COMBO Assay
• Alba Elution Kit
• Alba OEM Solutions
• Alba Quotient Services

Quantifiable outcome

• Up to 28501 multiplexed results per hour (largest panel under development - AllergyPlex COMBO)
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core.

• Ilex MedicalcoreChannel Partner/ Reseller/ Distributor · 16 February 2026AliveDx Suisse S.A. signed a strategic distribution agreement with Ilex Medical authorizing the distribution of MosaiQ and LumiQ solutions in Israel. This partnership represents an important milestone in AliveDx's strategy to expand its footprint in key markets and support healthcare providers with innovative diagnostic technologies.
• Hospital Supply Corporation (HSC)coreChannel Partner/ Reseller/ Distributor · 12 February 2026AliveDx Suisse S.A. signed a strategic distribution agreement with Hospital Supply Corporation (HSC), Pakistan. HSC is authorized to distribute AliveDx's MosaiQ and LumiQ solutions across Pakistan. This partnership represents an important milestone in AliveDx's expansion in South Asia and reinforces its commitment to working with established local partners to deliver innovative, high-value diagnostic technologies.
• Address MedicalcoreChannel Partner/ Reseller/ Distributor · 11 February 2026AliveDx Suisse S.A. signed a strategic distribution agreement with Address Medical authorizing the distribution of MosaiQ and LumiQ solutions in United Arab Emirates. This partnership represents another important milestone in AliveDx's strategy to expand its footprint in key emerging markets and support healthcare providers with innovative diagnostic technologies.
• DPC Lebanon (Diagnostic Products Corporation Lebanon Sarl)coreChannel Partner/ Reseller/ Distributor · 10 February 2026AliveDx Suisse S.A. signed a strategic distribution agreement with DPC Lebanon authorizing the distribution of MosaiQ and LumiQ solutions across Lebanon. This partnership represents an important milestone in AliveDx's expansion in the Middle East through established local partners.
• Reacting SarlcoreChannel Partner/ Reseller/ Distributor · 1 February 2026AliveDx Suisse S.A. signed a strategic distribution agreement with Reacting Sarl authorizing the distribution of MosaiQ and LumiQ solutions across Morocco. This partnership represents a further step in AliveDx's expansion across North Africa and underscores its commitment to working with strong local partners to deliver innovative diagnostic technologies.
• Medipac Technologies LtdcoreChannel Partner/ Reseller/ Distributor · 19 November 2025AliveDx signed a strategic distribution agreement with Medipac Technologies Ltd, a leading healthcare-solutions provider in Bangladesh. Medipac Technologies Ltd distributes AliveDx's MosaiQ and LumiQ diagnostic platforms across Bangladesh, effective immediately. This collaboration strengthens AliveDx's commitment to expanding its presence in high-growth emerging markets.
• TransmediccoreChannel Partner/ Reseller/ Distributor · 25 August 2025AliveDx Suisse S.A. and Transmedic Indonesia, Thailand, and Singapore signed a second distribution agreement enabling Transmedic to distribute the LumiQ solution across these markets in addition to the MosaiQ platform from the first agreement. This partnership underscores AliveDx's dedication to expanding its global footprint and delivering clinical and economic value to clinicians.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Roche Diagnostics: Roche cobas immunoassay systems include autoimmune and infectious disease testing serving the same hospital and reference laboratory customers. Roche is a much larger broad-line incumbent that competes in multiplex autoimmune disease diagnostics.
• Siemens Healthineers: Siemens Healthineers offers ADVIA Centaur, Atellica, and other immunoassay platforms for infectious disease, autoimmune, and allergy testing. It is a broad-line incumbent rather than an autoimmune/allergy specialist.
• Ortho Clinical Diagnostics: Ortho Clinical Diagnostics is a major player in transfusion medicine and immunohematology, directly competing with AliveDx's Alba blood bank reagents. It is a broader incumbent in blood bank diagnostics rather than a focused autoimmune specialist.
• Abbott Diagnostics: Abbott Diagnostics is a broad IVD incumbent with ARCHITECT and Alinity immunoassay systems that overlap with autoimmune and allergy testing menus. It is a much larger player and offers broader diagnostics portfolios rather than specializing in multiplex autoimmune and allergy testing.

Direct peers

• BIO-RAD Laboratories: BIO-RAD competes in autoimmune multiplex diagnostics (BioPlex 2200) and is a major supplier of immunohematology and blood bank reagents. Its product, customer base, and dual autoimmune + blood bank focus closely mirror AliveDx's portfolio.
• Bühlmann Laboratories: Bühlmann is a Swiss specialty diagnostics company focused on autoimmune and inflammatory disease testing, including calprotectin and celiac assays. It is comparable as a similarly-sized niche immunology vendor targeting clinical laboratories.
• Thermo Fisher Scientific (Phadia / ImmunoCAP): Phadia, the immunoassay arm of Thermo Fisher, is the market leader in allergy diagnostics with ImmunoCAP and competes in autoimmune diagnostics. It is the most direct competitor to AliveDx's MosaiQ and LumiQ platforms and serves the same hospital and reference laboratory customers.
• AESKU Group: AESKU specializes in autoimmune diagnostics including IFA, ELISA, and immunoblot products for the same clinical laboratory customers as AliveDx. It is similarly specialized in autoimmune and offers comparable technology approaches.
• EUROIMMUN (PerkinElmer / Revvity): EUROIMMUN is a leader in autoimmune diagnostics with a broad IFA, ELISA, and microarray menu. It serves the same clinical laboratory and hospital customer base with comparable autoimmune disease test panels and is acquired by Revvity (formerly PerkinElmer).

Emerging players

• Fujirebio: Fujirebio is a specialty diagnostics player with focus on autoimmune, infectious disease, and oncology assays. It is comparable as a specialty immunoassay vendor targeting overlapping clinical lab segments, though with a narrower multiplex microarray focus than AliveDx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/alivedx_com
• LinkedInlinkedin.com/company/alivedx

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AliveDx